Older adults and people with certain medical conditions are more likely to receive the respiratory syncytial virus (RSV) ...

The authors assessed the patient characteristics associated with RSV vaccination among older adults hospitalized during the ...

The European Commission approved Pfizer's respiratory syncytial virus vaccine for the prevention of lower respiratory tract ...

The bivalent respiratory syncytial virus prefusion F vaccine is highly effective and well tolerated against RSV-associated ...

The risk for new-onset or recurrent AF was not increased among older adult patients with preexisting conditions following RSV vaccination.

Population-based analyses of new vaccination programmes provide robust real-world evidence for post-licensure vaccine ...

By Blake Brittain (Reuters) -British pharmaceutical giant GlaxoSmithKline and rival Pfizer have agreed to end a lawsuit that ...

The second infection was also tied to a 50% or greater increase in several specific long-COVID conditions, including ...

The latest decision makes Pfizer's Abrysvo the first RSV vaccine approved for use in non-pregnant adults under 50 years of ...

Australian medicines regulator, the Therapeutic Goods Administration (TGA), has granted approval for mRESVIA (mRNA-1345), an ...

Pfizer Inc. (NYSE: PFE) announced today that the European Commission (EC) has issued a decision amending the marketing ...

"This approval underscores our commitment to protecting older adults from RSV-related respiratory diseases. We look forward to supplying mRESVIA from our Melbourne facility to older Australians ...